A Study of Canakinumab in Patients With Systemic Juvenile Idiopathic Arthritis or Hereditary Periodic Fevers Who Participated in the CACZ885G2301E1, CACZ885G2306 or CACZ885N2301 Studies
A French Open-label Extension Study of Canakinumab in Patients Who Participated in International Phase III Studies CACZ885G2301E1 or CACZ885G2306 in Systemic Juvenile Idiopathic Arthritis and CACZ885N2301 in Hereditary Periodic Fevers (TRAPS, HIDS, or crFMF)
Sponsor: Novartis Pharmaceuticals
A PHASE3 clinical study on Hereditary Periodic Fevers and Systemic Juvenile Idiopathic Arthritis, this trial is completed. The trial is conducted by Novartis Pharmaceuticals and has accumulated 11 data snapshots since 2014. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
11 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE3
-
Jun 2020 — Jan 2021 [monthly]
Completed PHASE3
▶ Show 6 earlier versions
-
Feb 2019 — Jun 2020 [monthly]
Completed PHASE3
Status: Active Not Recruiting → Completed
-
Jan 2019 — Feb 2019 [monthly]
Active Not Recruiting PHASE3
-
Jun 2018 — Jan 2019 [monthly]
Active Not Recruiting PHASE3
-
Mar 2018 — Jun 2018 [monthly]
Active Not Recruiting PHASE3
Status: Recruiting → Active Not Recruiting
-
May 2017 — Mar 2018 [monthly]
Recruiting PHASE3
Status: Active Not Recruiting → Recruiting · Phase: PHASE4 → PHASE3
-
Jan 2017 — May 2017 [monthly]
Active Not Recruiting PHASE4
First recorded
Nov 2014
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Novartis Pharmaceuticals
For direct contact, visit the study record on ClinicalTrials.gov .